Use of Obesity Biomarkers in Cardiovascular Epidemiology

Obesity is an established risk factor for cardiovascular disease (CVD), yet, the underlying mechanisms are only poorly understood. The adipose tissue produces a variety of hormones and cytokines and thereby actively participates in a network of biomarkers that may be relevant for the development of...

Full description

Bibliographic Details
Main Author: Tobias Pischon
Format: Article
Language:English
Published: Hindawi Limited 2009-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.3233/DMA-2009-0634
id doaj-3f82310b579d4234b4b4bcb0b059c71e
record_format Article
spelling doaj-3f82310b579d4234b4b4bcb0b059c71e2020-11-24T23:16:58ZengHindawi LimitedDisease Markers0278-02401875-86302009-01-01265-624726310.3233/DMA-2009-0634Use of Obesity Biomarkers in Cardiovascular EpidemiologyTobias Pischon0Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, GermanyObesity is an established risk factor for cardiovascular disease (CVD), yet, the underlying mechanisms are only poorly understood. The adipose tissue produces a variety of hormones and cytokines and thereby actively participates in a network of biomarkers that may be relevant for the development of CVD. Such obesity biomarkers have a great potential to better characterize the obesity phenotype that may be relevant for the risk of CVD beyond anthropometric parameters. They may be used to support mechanistic studies, to help identify individuals at risk for CVD, and to evaluate the effect of preventive measures. The present article discusses the role of some of the most promising obesity biomarkers in cardiovascular epidemiology, including inflammatory markers, adiponectin, resistin, and fetuin-A. Importantly, some of these markers have been related to cardiovascular risk even after accounting for anthropometric parameters. Further, the potential ability to manipulate blood levels of some of these biomarkers through medication, diet and lifestyle make them attractive markers for cardiovascular risk. However, many open questions remain – especially with regard to the causal role of the factors as well as with regard to the extent of improvement in CVD prediction by these markers – before measurement of these biomarkers may be recommended on a public health level.http://dx.doi.org/10.3233/DMA-2009-0634
collection DOAJ
language English
format Article
sources DOAJ
author Tobias Pischon
spellingShingle Tobias Pischon
Use of Obesity Biomarkers in Cardiovascular Epidemiology
Disease Markers
author_facet Tobias Pischon
author_sort Tobias Pischon
title Use of Obesity Biomarkers in Cardiovascular Epidemiology
title_short Use of Obesity Biomarkers in Cardiovascular Epidemiology
title_full Use of Obesity Biomarkers in Cardiovascular Epidemiology
title_fullStr Use of Obesity Biomarkers in Cardiovascular Epidemiology
title_full_unstemmed Use of Obesity Biomarkers in Cardiovascular Epidemiology
title_sort use of obesity biomarkers in cardiovascular epidemiology
publisher Hindawi Limited
series Disease Markers
issn 0278-0240
1875-8630
publishDate 2009-01-01
description Obesity is an established risk factor for cardiovascular disease (CVD), yet, the underlying mechanisms are only poorly understood. The adipose tissue produces a variety of hormones and cytokines and thereby actively participates in a network of biomarkers that may be relevant for the development of CVD. Such obesity biomarkers have a great potential to better characterize the obesity phenotype that may be relevant for the risk of CVD beyond anthropometric parameters. They may be used to support mechanistic studies, to help identify individuals at risk for CVD, and to evaluate the effect of preventive measures. The present article discusses the role of some of the most promising obesity biomarkers in cardiovascular epidemiology, including inflammatory markers, adiponectin, resistin, and fetuin-A. Importantly, some of these markers have been related to cardiovascular risk even after accounting for anthropometric parameters. Further, the potential ability to manipulate blood levels of some of these biomarkers through medication, diet and lifestyle make them attractive markers for cardiovascular risk. However, many open questions remain – especially with regard to the causal role of the factors as well as with regard to the extent of improvement in CVD prediction by these markers – before measurement of these biomarkers may be recommended on a public health level.
url http://dx.doi.org/10.3233/DMA-2009-0634
work_keys_str_mv AT tobiaspischon useofobesitybiomarkersincardiovascularepidemiology
_version_ 1725585530929807360